Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga Newsdesk www.benzinga.com Negative 92.8%

Neg 92.8% Neu 0% Pos 0%

Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $500 to $350.